

RECEIVED
TECH CENTER 1600/2900

PATENT
03 JAN 34 2003 ATTORNEY DOCKET NO. 50291/002001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#5

Applicant: Robert Chalifour et al. Art Unit: 1614
Serial No.: 10/009,122 Examiner: Not yet assigned
Filed: June 18, 2002 Customer No.: 21559
Title: Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof

TECH CENTER 1600/2900

FEB 04 2003

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account
No. 03-2095.

Respectfully submitted,

Date: January 31, 2003

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
50291.002001 Information Disclosure Statement.doc



21559
PATENT TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50291/002001

Serial No.

10/009,122

Applicant

Robert Chalifour et al.

Filing Date

June 18, 2002

Group

1614

03 JAN 24 11:23

RECEIVED
FEB 04 2003
TECH CENTER 1600/2900

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,470,951	11/28/95	Roberts			
	5,514,548	05/07/96	Krebber et al.			
	5,578,451	11/26/96	Nishimoto			
	5,652,334	07/29/97	Roberts			
	5,688,651	11/18/97	Solomon			
	5,721,130	02/24/98	Seubert et al.			
	5,753,624	05/19/98	McMichael et al.			
	5,817,626	10/06/98	Findeis et al.			
	5,837,672	11/17/98	Schenk et al.			
	5,851,996	12/22/98	Kline			
	5,854,204	12/29/98	Findeis et al.			
	5,854,215	12/29/98	Findeis et al.			
	5,869,093	02/09/99	Weiner et al.			
	5,891,991	04/06/99	Wasco et al.			
	5,985,242	11/16/99	Findeis et al.			
	6,261,569 B1	07/17/01	Comis et al.			
	6,277,826 B1	08/21/01	Findeis et al.			
	6,303,567 B1	10/16/01	Findeis et al.			
	6,319,498 B1	11/20/01	Findeis et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50291/002001
	Serial No.	10/009,122
	Applicant	Robert Chalifour et al.
	Filing Date	June 18, 2002
	Group	1614

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 94/05311	17.03.94	WIPO			
	WO 94/14836	07.07.94	WIPO			
	WO 94/19692	01.09.94	WIPO			
	WO 95/05393	23.02.95	WIPO			
	WO 95/05849	02.03.95	WIPO			
	WO 95/08999	06.04.95	WIPO			
	WO 95/12815	11.05.95	WIPO			
	WO 95/23166	31.08.95	WIPO			
	WO 95/31996	30.11.95	WIPO			
	WO 96/13583	09.05.96	WIPO			
	WO 96/28471	19.09.96	WIPO			
	WO 96/34887	07.11.96	WIPO			
	WO 96/37621	28.11.96	WIPO			
	WO 97/08320	06.03.97	WIPO			
	WO 97/32017	04.09.97	WIPO			
	WO 98/02462	22.01.98	WIPO			
	WO 98/05350	12.02.98	WIPO			
✓	WO 98/08868	05.03.98	WIPO			
	WO 98/22120	28.05.98	WIPO			
	WO 99/06587	11.02.99	WIPO			
	WO 99/27944	10.06.99	WIPO			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED

FEB 04 2003

TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50291/002001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No. 10/009,122	
(37 C.F.R. § 1.98(b))				Applicant Robert Chalifour et al.	
				Filing Date June 18, 2002	
				Group 1614	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION					
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass
	WO 99/27949	10.06.99	WIPO		
	WO 99/58564	18.11.99	WIPO		
	WO 99/60021	25.11.99	WIPO		
	WO 99/60024	25.11.99	WIPO		
	WO 00/20027	13.04.00	WIPO		
	WO 00/26238	11.05.00	WIPO		
	WO 00/43039	27.07.00	WIPO		
	WO 00/52048 A1	08.09.00	WIPO		
✓	WO 00/68263	16.11.00	WIPO		
	EP 0 584 452 A1	02.03.94	European		
	EP 0 752 886 B1	15.01.97	European		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
Benkirane et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," Journal of Biological Chemistry 258:26279-26285 (1998).					
Findeis et al., "Modified-Peptide Inhibitors of Amyloid β -Peptide Polymerization," Biochemistry 38:6791-6800 (1999).					
Flood et al., "Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-Activity Studies: Relation to Amnestic Effect of Amyloid β Protein," Proc. Natl. Acad. Sci. USA 91:380-384 (1994).					
Giulian et al., "The HHQK Domain of β -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," The Journal of Biological Chemistry 273:29719-29726 (1998).					
Sela et al., "Different Roles of D-Amino Acids in Immune Phenomena," FASEB J., 11:449-456 (1997).					
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

RECEIVED

TECH CENTER
FEB 04 2003
1600/2900
Translation
Yes/No

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. Serial No. Applicant Filing Date Group	50291/002001 10/009,122 Robert Chalifour et al. June 18, 2002 1614
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Tjernberg et al., "Arrest of β -Amyloid Fibril Formation by a Pentapeptide Ligand," Journal of Biological Chemistry 271:8545-8548 (1996).		
	Tjernberg et al., "Controlling Amyloid β -Peptide Fibril Formation with Protease-Stable Ligands," Journal of Biological Chemistry 272:12601-12605 (1997).		
	Tjernberg et al., "Controlling Amyloid β -Peptide Fibril Formation with Protease-Stable Ligands," Journal of Biological Chemistry 272:17894 (1997).		
	Torneiro et al., "Sequence-Selective Binding of Peptides in Water by a Synthetic Receptor Molecule," J. Am. Chem. Soc. 117:5887-5888 (1995).		
	Van Regenmortel et al., "D-peptides as Immunogens and Diagnostic Reagents," Current Opinion in Biotechnology 9:377-382 (1998).		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

RECEIVED
 FEB 04 2003
 TECH CENTER 1600/2900